Intranasal glucocorticosteroids in acute rhinosinusitis: prescribe or not prescribe?

Abstract

According to the global and Russian medical care standards, intranasal glucocorticosteroids (InGCS) are included in the treatment regimen for acute rhinosinusitis (ARS). The medications are recommended as monotherapy in milder forms of the disease and in combination with systemic antibiotics in uncomplicated moderate to severe ARS. This is explained by the fact that in most cases ARS has viral rather than bacterial etiology. The author reviews a considerable number of studies demonstrating the efficacy of InGCS in ARS as a potent and safe anti-inflammatory treatment. It is emphasized that of all drugs in the group only Nasonex has ARS without signs of severe bacterial infection as registered indication.

Keywords

• интраназальные глюкокортикостероиды
• острый риносинусит
• intranasal glucocorticosteroids
• acute rhinosinusitis